Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients With High-Risk Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), and Myelodysplastic Syndrome (MDS)

Key facts

Sponsor

University of Illinois at Chicago

Principal Investigator

Matias Sanchez, MD

University of Illinois at Chicago

Intervention

Intensity modulated total marrow irradiation(radiation)

Enrollment

38 enrolled

Eligibility

18-65 years · All sexes

Timeline

2025 – 2032

Study locations (1)

• University of Illinois Cancer Center, Chicago, Illinois, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Myelodysplastic syndrome

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT06630221
  Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations
  Abhay Singh, MD MPH
• RECRUITINGPHASE1, PHASE2NCT06548230
  A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
  M.D. Anderson Cancer Center
• ACTIVE NOT RECRUITINGPHASE2NCT07052006
  A Phase 2a Study of HT-6184 in Subjects With IPSS-R Very Low, Low or Intermediate Risk MDS and Anemia
  Halia Therapeutics, Inc.
• ACTIVE NOT RECRUITINGPHASE2NCT05201066
  Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.
  Novartis Pharmaceuticals
• RECRUITINGNANCT06886425
  Involvement of CDA and/or dCK Metabolizing Enzymes in the Response to Azacytidine Treatment of Patients With Hematologic Malignancies
  Assistance Publique Hopitaux De Marseille
• ACTIVE NOT RECRUITINGPHASE3NCT04401748
  Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome
  AbbVie
• ACTIVE NOT RECRUITINGPHASE2NCT02912208
  Eltrombopag for the Treatment of Thrombocytopenia Due to Low- and Intermediate Risk Myelodysplastic Syndromes
  Associazione Qol-one

See all trials for Myelodysplastic syndrome →